Drug Description in Trials / DrugBank / KEGG DRUG
Search results
No. | Drug (Description in trials) | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | Disease ID |
---|---|---|---|---|---|---|
1 | ANTI-VON willebrand factor nanobody, caplacizumab (D11160) | - | - | - | - | [1] 64 64 💬
|
2 | ANTI-VON willebrand factor nanobody, INN = caplacizumab (D11160) | [1] Caplacizumab Caplacizumab | [1] Caplacizumab
Caplacizumab
(D11160) 💬
| [1] VWF VWF 💬
| [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 💬
|
3 | Caplacizumab (D11160) | [1] Caplacizumab Caplacizumab | [1] Caplacizumab
Caplacizumab
(D11160) 💬
| [1] VWF VWF 💬
| [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [2] 63 63, 64 💬
|